Cuba’s National Regulatory Authority & COVID-19:
July–October 2021, Vol 23, No 3–4

At the time of this writing, more than 10 million Cubans (nearly 90% of the country’s population), had received at least their first dose of Soberana 02 or Abdala, two of five vaccine candidates for SARS-CoV-2 developed and produced on the island. Late-phase clinical trial data revealed that Abdala is 92.28% effective after the full, […]

Read More
Monoclonal Antibodies vs COVID-19:
April 2021, Vol 23, No 2

Cuba has five COVID-19 vaccines in clinical trials and is on track to receive emergency use authorization from the country’s regulatory agency to begin mass vaccination with two of those candidates: Abdala and SOBERANA 02. Results from phase 1 and 2 trials of these vaccines, the first developed and produced in Latin America, have been […]

Read More
COVID-19 Requires Innovation, Regulation and Rigor:
April 2021, Vol 23, No 2

The effects and implications of COVID-19 are global, comprehensive and long-term. The pandemic has exposed inequities, the fragility of economic and political systems, and in many cases, skewed priorities. Population health, not to mention planetary health, is suffering as a result. Nevertheless, the global health crisis in which we are embroiled has provided opportunities for […]

Read More
Mobilizing Primary Health Care: Cuba’s Powerful Weapon against COVID-19
April 2020, Vol 22, No 2

A strong foundation of primary care is critical to the health system and is particularly important during pandemics like COVID-19. Primary care practices should be a natural fit for triaging, testing, treating, and educating patients. —Corinne Lewis, Shanoor Seervai, Tanya Shah,Melinda K. Abrams, and Laurie Zephyrin MDThe Commonwealth Fund, April 22, 2020[1] This thoughtful observation […]

Read More
Early Online

No new Early Online articles at this time. The most recent articles are listed in the Current Issue Table of Contents. Early Online articles are added as soon as they are available, so please check back later.